Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research note released on Thursday.

Several other equities research analysts also recently weighed in on the company. The Goldman Sachs Group increased their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. reissued a neutral rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Cantor Fitzgerald reissued an overweight rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. Finally, Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an outperform rating in a report on Tuesday, June 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $50.67.

Agios Pharmaceuticals Stock Up 2.1 %

Shares of AGIO opened at $44.39 on Thursday. The stock has a 50 day moving average price of $40.13 and a 200 day moving average price of $31.81. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -7.02 and a beta of 0.79. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $49.06.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. The firm had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The firm’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.47) earnings per share. On average, equities analysts anticipate that Agios Pharmaceuticals will post -2.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Quest Partners LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter worth $41,000. China Universal Asset Management Co. Ltd. raised its position in Agios Pharmaceuticals by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 5,040 shares in the last quarter. NEOS Investment Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter worth $210,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Agios Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 942 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its position in Agios Pharmaceuticals by 31.8% in the fourth quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 2,900 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.